These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 37461950)
1. P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study. Sands B; Pondel M; Silver M; Petersen A; Wolf D; Panaccione R; Loftus E; Colombel JF; Sturm A; D'Haens G Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S8. PubMed ID: 37461950 [TBL] [Abstract][Full Text] [Related]
2. P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study. Hudesman D; Long M; Wolf D; Hanauer S; Ghosh S; Petersen A; Pondel M; Silver M; Cross R; Feagan B Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9. PubMed ID: 37461954 [TBL] [Abstract][Full Text] [Related]
3. P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial. Colombel JF; D'Haens G; Irving P; Petersen A; Chitkara D; Marta C; Chen T; Charles L; Danese S; Ghosh S Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9. PubMed ID: 37461956 [TBL] [Abstract][Full Text] [Related]
4. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. Sandborn WJ; Feagan BG; D'Haens G; Wolf DC; Jovanovic I; Hanauer SB; Ghosh S; Petersen A; Hua SY; Lee JH; Charles L; Chitkara D; Usiskin K; Colombel JF; Laine L; Danese S; N Engl J Med; 2021 Sep; 385(14):1280-1291. PubMed ID: 34587385 [TBL] [Abstract][Full Text] [Related]
5. Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies. Sands BE; D'Haens G; Panaccione R; Regueiro M; Ghosh S; Hudesman D; Ahmad HA; Mehra D; Wu H; Jain A; Petersen A; Osterman MT; Afzali A; Danese S Clin Gastroenterol Hepatol; 2024 Oct; 22(10):2084-2095.e4. PubMed ID: 38723981 [TBL] [Abstract][Full Text] [Related]
6. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625 [TBL] [Abstract][Full Text] [Related]
7. Ozanimod: A Review in Ulcerative Colitis. Paik J Drugs; 2022 Aug; 82(12):1303-1313. PubMed ID: 35994200 [TBL] [Abstract][Full Text] [Related]
8. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S; Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801 [TBL] [Abstract][Full Text] [Related]
9. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ; Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. Danese S; Panaccione R; Abreu MT; Rubin DT; Ghosh S; Dignass A; Afzali A; Wolf DC; Chiorean MV; Vermeire S; Jain A; Charles L; Lawlor G; Osterman MT; Wu H; Canavan JB; Petersen A; Colombel JF; Regueiro M J Crohns Colitis; 2024 Feb; 18(2):264-274. PubMed ID: 37651686 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327 [TBL] [Abstract][Full Text] [Related]
12. Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis. Choi D; Stewart AP; Bhat S Ann Pharmacother; 2022 May; 56(5):592-599. PubMed ID: 34423657 [TBL] [Abstract][Full Text] [Related]
13. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574 [TBL] [Abstract][Full Text] [Related]
14. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166 [TBL] [Abstract][Full Text] [Related]
15. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis. Vickers AD; Ainsworth C; Mody R; Bergman A; Ling CS; Medjedovic J; Smyth M PLoS One; 2016; 11(10):e0165435. PubMed ID: 27776175 [TBL] [Abstract][Full Text] [Related]
16. Update on ozanimod for ulcerative colitis. Antonelli EK; Del Sordo R; Morelli O; Villanacci V; Bassotti G Drugs Today (Barc); 2022 Jul; 58(7):351-367. PubMed ID: 35851870 [TBL] [Abstract][Full Text] [Related]
17. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program. Feagan BG; Schreiber S; Afzali A; Rieder F; Hyams J; Kollengode K; Pearlman J; Son V; Marta C; Wolf DC; D'Haens GG Contemp Clin Trials; 2022 Nov; 122():106958. PubMed ID: 36208720 [TBL] [Abstract][Full Text] [Related]
18. Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials. Vermeire S; Sands BE; Peyrin-Biroulet L; D'Haens GR; Panés J; Yarur AJ; Wolf DC; Ritter T; Schreiber S; Woolcott JC; Modesto I; Keating M; Shan K; Wu J; Chiorean MV; Baert F; Dubinsky MC; Goetsch M; Danese S; Feagan BG J Crohns Colitis; 2024 Jun; ():. PubMed ID: 38877972 [TBL] [Abstract][Full Text] [Related]
19. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. Loftus EV; Sands BE; Colombel JF; Dotan I; Khalid JM; Tudor D; Geransar P Clin Exp Gastroenterol; 2020; 13():211-220. PubMed ID: 32606883 [TBL] [Abstract][Full Text] [Related]
20. P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis. Long M; Cross R; Calkwood J; Pondel M; Pai A; Ahmad H; Charles L; Elegbe A; Petersen A; Sheffield J; Javed A; Wolf D Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9-S10. PubMed ID: 37461957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]